These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38864641)

  • 1. No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study.
    Ishii J; Nishikimi M; De Bus L; De Waele J; Takaba A; Kuriyama A; Kobayashi A; Tanaka C; Hashi H; Hashimoto H; Nashiki H; Shibata M; Kanamoto M; Inoue M; Hashimoto S; Katayama S; Fujiwara S; Kameda S; Shindo S; Komuro T; Kawagishi T; Kawano Y; Fujita Y; Kida Y; Hara Y; Yoshida H; Fujitani S; Shime N;
    Microbiol Spectr; 2024 Jul; 12(7):e0034224. PubMed ID: 38864641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study.
    Chang Y; Jeon K; Lee SM; Cho YJ; Kim YS; Chong YP; Hong SB
    J Korean Med Sci; 2021 Oct; 36(41):e251. PubMed ID: 34697926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotics for ventilator-associated pneumonia.
    Arthur LE; Kizor RS; Selim AG; van Driel ML; Seoane L
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004267. PubMed ID: 27763732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenems and subsequent multiresistant bloodstream infection: does treatment duration matter?
    Donaldson AD; Razak L; Liang LJ; Fisher DA; Tambyah PA
    Int J Antimicrob Agents; 2009 Sep; 34(3):246-51. PubMed ID: 19628129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of broad-spectrum antimicrobials for more than 72 h and the detection of multidrug-resistant bacteria in Japanese intensive care units: a multicenter retrospective cohort study.
    Yoshida H; Motohashi T; De Bus L; De Waele J; Takaba A; Kuriyama A; Kobayashi A; Tanaka C; Hashi H; Hashimoto H; Nashiki H; Shibata M; Kanamoto M; Inoue M; Hashimoto S; Katayama S; Fujiwara S; Kameda S; Shindo S; Suzuki T; Komuro T; Kawagishi T; Kawano Y; Fujita Y; Kida Y; Hara Y; Fujitani S;
    Antimicrob Resist Infect Control; 2022 Sep; 11(1):119. PubMed ID: 36175948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study.
    Meier N; Munch MW; Granholm A; Perner A; Hertz FB; Venkatesh B; Hammond NE; Li Q; De Bus L; De Waele J; Kauzonas E; Sjövall F; Møller MH; Helleberg M
    Acta Anaesthesiol Scand; 2024 Jul; 68(6):821-829. PubMed ID: 38549422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis.
    Sadyrbaeva-Dolgova S; Aznarte-Padial P; Pasquau-Liaño J; Expósito-Ruiz M; Calleja Hernández MÁ; Hidalgo-Tenorio C
    Int J Infect Dis; 2019 Aug; 85():80-87. PubMed ID: 31075508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience.
    Karruli A; Boccia F; Gagliardi M; Patauner F; Ursi MP; Sommese P; De Rosa R; Murino P; Ruocco G; Corcione A; Andini R; Zampino R; Durante-Mangoni E
    Microb Drug Resist; 2021 Sep; 27(9):1167-1175. PubMed ID: 33600262
    [No Abstract]   [Full Text] [Related]  

  • 9. Carbapenem use in critically ill patients.
    Patrier J; Timsit JF
    Curr Opin Infect Dis; 2020 Feb; 33(1):86-91. PubMed ID: 31815750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study.
    Barbier F; Dupuis C; Buetti N; Schwebel C; Azoulay É; Argaud L; Cohen Y; Hong Tuan Ha V; Gainnier M; Siami S; Forel JM; Adrie C; de Montmollin É; Reignier J; Ruckly S; Zahar JR; Timsit JF;
    Crit Care; 2024 Jan; 28(1):10. PubMed ID: 38172969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting acquisition of carbapenem-resistant Gram-negative pathogens in intensive care units.
    Dantas LF; Dalmas B; Andrade RM; Hamacher S; Bozza FA
    J Hosp Infect; 2019 Oct; 103(2):121-127. PubMed ID: 31039381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.
    Bass SN; Bauer SR; Neuner EA; Lam SW
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3748-53. PubMed ID: 25845872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Microbial Factors of Healthcare-Associated Infections Including Multidrug-Resistant Pathogens and Antibiotic Consumption at the University Intensive Care Unit in Poland in the Years 2011-2018.
    Litwin A; Fedorowicz O; Duszynska W
    Int J Environ Res Public Health; 2020 Sep; 17(19):. PubMed ID: 32977435
    [No Abstract]   [Full Text] [Related]  

  • 14. Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network.
    Rello J; Sarda C; Mokart D; Arvaniti K; Akova M; Tabah A; Azoulay E;
    Eur J Clin Microbiol Infect Dis; 2020 Feb; 39(2):385-392. PubMed ID: 31707508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey.
    Rello J; Kalwaje Eshwara V; Conway-Morris A; Lagunes L; Alves J; Alp E; Zhang Z; Mer M;
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1235-1240. PubMed ID: 30900056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of antibiotic pressure on multi-drug resistant
    Ruiz J; Gordon M; Villarreal E; Frasquet J; Sánchez MÁ; Martín M; Castellanos Á; Ramirez P
    Antimicrob Resist Infect Control; 2019; 8():38. PubMed ID: 30809381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
    Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
    Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients.
    De Pascale G; Carelli S; Vallecoccia MS; Cutuli SL; Taccheri T; Montini L; Bello G; Spanu T; Tumbarello M; Cicchetti A; Urbina I; Oradei M; Marchetti M; Antonelli M
    J Crit Care; 2019 Apr; 50():169-176. PubMed ID: 30553184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for hospitalized patients with resistant or multidrug-resistant
    Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
    Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.